Zhang Haixin, Zhu Rongyu, Sun Quanhao, Du Likun
School of Graduate Students, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
The Second Department of Endocrine Diseases, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Front Endocrinol (Lausanne). 2025 Aug 13;16:1619462. doi: 10.3389/fendo.2025.1619462. eCollection 2025.
The elevated global prevalence of metabolic syndrome and type 2 diabetes mellitus (T2DM) has led to a dramatic increase in patients with insulin resistance. The majority of insulin resistance is closely associated with obesity and metabolic syndrome, resulting in impaired insulin signaling pathways. type 2 diabetes can be preceded by insulin resistance, and therefore, it is crucial to stop the progression of insulin resistance to type 2 diabetes. Fibroblast growth factor 21 (FGF21) holds a bright future in the therapeutic study of insulin resistance; it is involved in the regulation of lipid metabolism and immune homeostasis while ameliorating the impaired insulin signaling pathway, improving the state of insulin resistance through multiple aspects. In this review, we describe the physiological properties and signaling pathways of FGF21 and elaborate on the mechanism of action of FGF21 in improving insulin resistance. Finally, the progress of FGF21 analog research is summarized in the context of the treatment of insulin resistance.
代谢综合征和2型糖尿病(T2DM)在全球范围内的患病率不断上升,导致胰岛素抵抗患者急剧增加。大多数胰岛素抵抗与肥胖和代谢综合征密切相关,导致胰岛素信号通路受损。2型糖尿病可先于胰岛素抵抗出现,因此,阻止胰岛素抵抗发展为2型糖尿病至关重要。成纤维细胞生长因子21(FGF21)在胰岛素抵抗的治疗研究中前景光明;它参与脂质代谢和免疫稳态的调节,同时改善受损的胰岛素信号通路,从多个方面改善胰岛素抵抗状态。在本综述中,我们描述了FGF21的生理特性和信号通路,并阐述了FGF21改善胰岛素抵抗的作用机制。最后,在胰岛素抵抗治疗的背景下总结了FGF21类似物研究的进展。